PeptideReference
Back to Peptide Library

Pramlintide (Symlin)

Pramlintide acetate

FDA Approved

Approved status applies to specific products, routes, and indications, not every use context discussed online.

An FDA-approved injectable medication (Symlin) taken at mealtimes alongside insulin by people with type 1 or type 2 diabetes. It mimics a natural hormone that slows digestion and helps you feel full, reducing blood sugar spikes after eating.

15 studiesUpdated 2026-03-13Subcutaneous injection (FDA-approved route; administered into abdomen or thigh, not arm due to variable absorption)
Clinical bottom lineApproved

Pramlintide (Symlin) is FDA-approved.

Use according to current labeled indication and prescribing guidance.

Safety Summary

Gastrointestinal adverse effects (nausea, vomiting) are the most common and are typically dose-dependent and transient, resolving with continued use and gradual titration. Nausea occurs in 30-50% of patients during initiation. The most clinically significant risk is severe hypoglycemia when used with insulin (FDA Boxed Warning), occurring primarily within the first 3 hours post-injection. This risk is managed by mandatory 50% reduction in mealtime insulin dose upon initiation and frequent blood glucose monitoring. Long-term safety studies up to 2 years show no organ toxicity, no cancer risk signals, no tolerance development, and no withdrawal effects. Cardiovascular safety analyses show no increased MACE risk. No consistent differences by gender, race, or age, PMC5630431, PMC2975690.

Clinical check-in

If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.

See cited studies on this page (15)

Cited sources

Every claim on this page links to one of the 15 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.

  1. 1PMID 11919132PubMed
  2. 2NCT01841359ClinicalTrials.gov
  3. 3PMID 20518811PubMed
  4. 4PMID 17504894PubMed
  5. 5Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysisReference
  6. 6Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes MellitusReference
  7. 7Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialReference
  8. 8Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetesReference
  9. 9Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular riskReference
  10. 10PMID 21199269PubMed
  11. 11Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug developmentReference
  12. 12Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 DiabetesReference
  13. 13NCT06422325ClinicalTrials.gov
  14. 14NCT04243629ClinicalTrials.gov
  15. 15Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 DiabetesReference